Program
HIF-2alpha Inhibitor HS-10516
Also written as “HS-10516 + Lenvatinib”, “Oral HS-10516” and “HS-10516”.
Its studies are mostly in Carcinoma, Renal Cell · von Hippel-Lindau Disease, led by Hansoh Pharmaceutical Group.
Furthest: phase 2, since Jul 30, 20253 company-led studies, 3 open or runningNext primary completion: Jul 10, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hansoh Pharmaceutical Group | 33 open or running | phase 2since Jul 30, 2025 | Sep 15, 2023 | Jul 10, 2027phase 2 · NCT07097935 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 15, 2023First study: phase 1 study in Carcinoma, Renal CellFirst studyNCT06049030 · 190 planned
- Aug 12, 2024Phase 1 study in von Hippel-Lindau DiseaseNCT06553339 · 60 planned · China
- Jul 30, 2025Phase 2 study in Advanced Clear Cell Renal Cell CarcinomaNCT07097935 · 104 planned · China
Ahead
- Jul 10, 2027Primary completion: phase 2 study in Advanced Clear Cell Renal Cell CarcinomaNCT07097935
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07097935Advanced Clear Cell Renal Cell Carcinoma · China | 2 | Recruiting | Jul 10, 2027 | 104 |
| NCT06553339von Hippel-Lindau Disease · China | 1 | Recruiting | Jul 31, 2026 | 60 |
| NCT06049030Carcinoma, Renal Cell | 1 | Not yet recruiting | Sep 25, 2024 | 190 |
How it is read
Names in the registry
- “HS-10516 + Lenvatinib”, 1 entry
- “Oral HS-10516”, 1 entry
- “HS-10516”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Renal Cell, 2 studies
- von Hippel-Lindau Disease, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.